Literature DB >> 26443578

Peroxisome Proliferator Activated Receptor-α Association With Silent Information Regulator 1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart.

Shin-ichi Oka1, Peiyong Zhai1, Takanobu Yamamoto1, Yoshiyuki Ikeda1, Jaemin Byun1, Chiao-Po Hsu1, Junichi Sadoshima2.   

Abstract

BACKGROUND: Heart failure is accompanied by changes in cardiac metabolism characterized by reduced fatty acid (FA) utilization. However, the underlying mechanism and its causative involvement in the progression of heart failure are poorly understood. The peroxisome proliferator activated receptor-α (PPARα)/retinoid X receptor (RXR) heterodimer promotes transcription of genes involved in FA metabolism through binding to the PPAR response element, called direct repeat 1 (DR1). Silent information regulator 1 (Sirt1) is a histone deacetylase, which interacts with PPARα. METHODS AND
RESULTS: To investigate the role of PPARα in the impaired FA utilization observed during heart failure, genetically altered mice were subjected to pressure overload. The DNA binding of PPARα, RXRα, and Sirt1 to DR1 was evaluated with oligonucleotide pull-down and chromatin immunoprecipitation assays. Although the binding of PPARα to DR1 was enhanced in response to pressure overload, that of RXRα was attenuated. Sirt1 competes with RXRα to dimerize with PPARα, thereby suppressing FA utilization in the failing heart. DR1 sequence analysis indicated that the typical DR1 sequence favors PPARα/RXRα heterodimerization, whereas the switch from RXRα to Sirt1 takes place on degenerate DR1s. Sirt1 bound to PPARα through a region homologous to the PPARα binding domain in RXRα. A short peptide corresponding to the RXRα domain not only inhibited the interaction between PPARα and Sirt1 but also improved FA metabolism and ameliorated cardiac dysfunction.
CONCLUSIONS: A change in the heterodimeric partner of PPARα from RXRα to Sirt1 is responsible for the impaired FA metabolism and cardiac dysfunction in the failing heart.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  DNA; fatty acids; heart failure; metabolism; peroxisome proliferator activated receptor–α

Mesh:

Substances:

Year:  2015        PMID: 26443578      PMCID: PMC4651813          DOI: 10.1161/CIRCHEARTFAILURE.115.002216

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  27 in total

Review 1.  Mitochondrial energy metabolism in heart failure: a question of balance.

Authors:  Janice M Huss; Daniel P Kelly
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

2.  Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization.

Authors:  Ivan Luptak; James A Balschi; Yanqiu Xing; Teresa C Leone; Daniel P Kelly; Rong Tian
Journal:  Circulation       Date:  2005-10-03       Impact factor: 29.690

3.  DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate.

Authors:  A Y Tu; J J Albers
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

4.  Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha.

Authors:  Zoltan Arany; Mikhail Novikov; Sherry Chin; Yanhong Ma; Anthony Rosenzweig; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-14       Impact factor: 11.205

5.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

Authors:  Brian N Finck; John J Lehman; Teresa C Leone; Michael J Welch; Michael J Bennett; Attila Kovacs; Xianlin Han; Richard W Gross; Ray Kozak; Gary D Lopaschuk; Daniel P Kelly
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

6.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth.

Authors:  P M Barger; J M Brandt; T C Leone; C J Weinheimer; D P Kelly
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.

Authors:  Frédéric Picard; Martin Kurtev; Namjin Chung; Acharawan Topark-Ngarm; Thanaset Senawong; Rita Machado De Oliveira; Mark Leid; Michael W McBurney; Leonard Guarente
Journal:  Nature       Date:  2004-06-02       Impact factor: 49.962

Review 8.  The PPAR trio: regulators of myocardial energy metabolism in health and disease.

Authors:  Jose A Madrazo; Daniel P Kelly
Journal:  J Mol Cell Cardiol       Date:  2008-04-04       Impact factor: 5.000

9.  Sirt1 regulates aging and resistance to oxidative stress in the heart.

Authors:  Ralph R Alcendor; Shumin Gao; Peiyong Zhai; Daniela Zablocki; Eric Holle; Xianzhong Yu; Bin Tian; Thomas Wagner; Stephen F Vatner; Junichi Sadoshima
Journal:  Circ Res       Date:  2007-04-19       Impact factor: 17.367

Review 10.  The nuclear receptor superfamily: the second decade.

Authors:  D J Mangelsdorf; C Thummel; M Beato; P Herrlich; G Schütz; K Umesono; B Blumberg; P Kastner; M Mark; P Chambon; R M Evans
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

View more
  24 in total

Review 1.  Cardiac nuclear receptors: architects of mitochondrial structure and function.

Authors:  Rick B Vega; Daniel P Kelly
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

2.  Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.

Authors:  Junco S Warren; Christopher M Tracy; Mickey R Miller; Aman Makaju; Marta W Szulik; Shin-Ichi Oka; Tatiana N Yuzyuk; James E Cox; Anil Kumar; Bucky K Lozier; Li Wang; June García Llana; Amira D Sabry; Keiko M Cawley; Dane W Barton; Yong Hwan Han; Sihem Boudina; Oliver Fiehn; Haley O Tucker; Alexey V Zaitsev; Sarah Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

3.  DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure.

Authors:  Mark E Pepin; Stavros Drakos; Chae-Myeong Ha; Martin Tristani-Firouzi; Craig H Selzman; James C Fang; Adam R Wende; Omar Wever-Pinzon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-12       Impact factor: 4.733

Review 4.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

5.  Both gain and loss of Nampt function promote pressure overload-induced heart failure.

Authors:  Jaemin Byun; Shin-Ichi Oka; Nobushige Imai; Chun-Yang Huang; Guersom Ralda; Peiyong Zhai; Yoshiyuki Ikeda; Shohei Ikeda; Junichi Sadoshima
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-26       Impact factor: 4.733

6.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 7.  The Modulating Effects of Cardiac Resynchronization Therapy on Myocardial Metabolism in Heart Failure.

Authors:  Yi-Zhou Xu; Chao-Feng Chen; Bin Chen; Xiao-Fei Gao; Wei Hua; Yong-Mei Cha; Petras P Dzeja
Journal:  Pacing Clin Electrophysiol       Date:  2016-12-07       Impact factor: 1.976

Review 8.  Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health.

Authors:  Dimitra Palioura; Antigone Lazou; Konstantinos Drosatos
Journal:  J Mol Cell Cardiol       Date:  2021-10-13       Impact factor: 5.000

9.  The olive constituent oleuropein, as a PPARα agonist, markedly reduces serum triglycerides.

Authors:  Foteini Malliou; Ioanna Andreadou; Frank J Gonzalez; Antigone Lazou; Eva Xepapadaki; Ioanna Vallianou; George Lambrinidis; Emmanuel Mikros; Marios Marselos; Alexios-Leandros Skaltsounis; Maria Konstandi
Journal:  J Nutr Biochem       Date:  2018-06-05       Impact factor: 6.048

Review 10.  The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

Authors:  Charikleia Kalliora; Konstantinos Drosatos
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.